Reducing relapse in psychosis through medication management.
Introduction Simonelli-Collen (2005) suggests that the concept of relapse is a complex, multidimensional phenomenon that is not uniformly defined in the research literature.
However, it is commonly understood as the re-emergence or worsening of signs and symptoms in individuals previously treated for psychoses (Birchwood & Spencer 2001) . Relapse is often thought to be indistinguishable from setting to setting with a similar client experience. However it is remarkable for its divergence in quantity of symptoms experienced by individuals, acceleration and duration of onset. Successful relapse prevention offers the potential of lowering treatment resistant symptoms and decelerating the clients' possible passage into severe and enduring mental illness (Birchwood & Spencer 2001) . Relapse prevention consists of strategies designed to assist the client and significant others to monitor the client's condition over time to detect early warning signs of impending psychoses and the implementation of an individualised action plan to offset the development of a 'full blown' psychotic episode. In addition, strategies to help the person to recognise and manage precipitating factors that lead to relapse such as stress are developed using a biopsychosocial approach. The importance of relapse prevention can perhaps be summarised by Birchwood et al (1993) who argued that many clients feel trapped by their illnesses, which may make them more prone to depression. Subsequently they have a strong interest in learning to recognise and avoid the re emergence of symptoms and possible re hospitalisation (Birchwood et al 1993) . Relapse prevention consists of multiple individualised approaches that are tailored to meet the diverse needs of clients who are attempting to manage their symptoms. Consequently the focus of the intervention is often psychosocial in nature. One strategy that has been consistently used in the management of symptoms is the use of psychotropic medications. This article focuses on medication management as one of the approaches used, in combination with others, to reduce relapse in clients with mental health problems.
Adherence with psychotropic medications.
The use of psychotropic medications remains one of the mainstays of psychiatric treatment however there is considerable evidence to suggest that many people do not take their medication as prescribed. It has been established that continuing on regular medication can significantly reduce relapse rates. Kisling (1994) has argued that if clients were completely adherent with their medication regimes, relapse rates would fall to about 15%. Consequently there has been an effort to target 'non-compliance' among those who are prescribed these medications. There is therefore an onus on mental health nurses to play a pivotal role in this process.
In recent years there has been recognition that the term 'compliance' is value-laden and suggests an authoritative relationship between the client and the prescriber/carer (Marland and Sharkey 1999) . Accordingly, the terminology has moved from 'compliance' to 'adherence' through to 'concordance' which suggests a partnership between client and prescriber and a more collaborative approach to care. These terms are still however used interchangeably in the available literature.
Factors affecting adherence to psychotropic medications.
The factors contributing to a client's decision not to take their medication as prescribed are numerous and diverse. These factors include: MHP161  Side-effect profile of prescribed medications: particularly side-effects such as extra-pyramidal side-effects which can be distressing and socially disfiguring but also effects such as weight gain and sexual dysfunction.
 Lack of insight into the illness: individuals may believe that they are not ill and therefore have no need to take medication.
 Clinical features of illness: e.g. paranoia or suspiciousness that may be present in certain illnesses.
 Secondary gain from illness: e.g. people who are manic may enjoy the feeling of elevation and may not want to take medication which they know will reduce this elevated mood.
 Lack of symptoms: this is particularly a problem for those who take medication prophylactically to prevent a re-occurrence of symptoms e.g.
Lithium in bipolar disorder.
 Refusal to accept diagnosis: if a client does not believe they have a mental health problem they may be reluctant to take psychotropic medication. Assessment of mental state: an initial assessment of the client's illness is important both prior to commencement of psychotropic medications and also during treatment to assess the medication efficacy. A baseline measurement of symptoms prior to administration of medications is also important to distinguish symptoms from side-effects. A scale such as the KGV symptom scale can be utilised (Krawiecka et al, 1977 ).
Assessment of side-effects: Assessing the severity of drug related side-effects is an important aspect of medication management. They may go undetected as clients may not report them and nurses may not ask about them (Bennett et al 1995) . A number of neuroleptic side-effect rating scales exist which can help to provide an accurate picture of the extent of side-effects and how they impinge on clients' lives. However, one that can be easily incorporated into nursing practice is the Liverpool University neuroleptic side-effect rating scale (LUNSERS) (Day et al 1995) . This 51-item scale asks the client to report the range of side-effects they have experienced and also elicits the stress which each side-effect causes the individual. Day et al (1995) identify that this scale is particularly useful as it can be administered by health care staff without special training, can be completed by acutely disturbed clients and only takes between 5-20 minutes to complete ensuring that it can be included in on-going nursing assessments. It is important to note that mental health nurses also have a key role in the symptomatic management of side-effects. Including non-medical interventions to alleviate common side-effects such as constipation, dry mouth and weight gain can be a crucial step in improving adherence with common psychotropic medications. These interventions could include dietary and lifestyle advice with a view to reducing/preventing constipation and weight gain and the use of an artificial saliva spray to help minimise the discomfort caused by dry mouth.
Compliance therapy (Kemp et al 1997) : this is a cognitive-behavioural intervention that has adapted techniques from motivational interviewing and psychoeducation. The Education is also a key component of compliance therapy and aims to provide information to clients about their illness and their medication to improve their understanding and increase adherence. It is reported that many clients are not provided with adequate information about the psychotropic medications prescribed to them (Gray et al 2005 , Happell et al 2004 . This may be a result of several different factors for example failure of the client to directly ask for information about their medications, a fear on the part of the health professional that giving full information about a medication may promote non-adherence or a reluctance on the part of the health professional to discuss certain side-effects with clients. Higgins et al (2005) cites the latter as an issue when looking at the side-effect of sexual dysfunction which may occur with some psychotropic medications, in particular antipsychotic and antidepressant medications. Addressing this issue Higgins et al (2005:444) suggest that "mental health nurses need to meet the challenge of informing service users with regard to these side effects, and supply education as to how some side effects may be diminished". However, while education is useful in improving people's knowledge about their medication, when used in isolation from the other components of compliance therapy, it does not increase adherence (Gray et al 2002) . Finally, compliance therapy also involves a behavioural component which is concerned with incorporating the medication regime into the everyday routine of the client. Utilising this behavioural component, clients are encouraged to link taking their medication with everyday routine behaviours such as mealtimes, going to bed etc. It would appear that this intervention may be more suited to those clients whose non-adherence with medication is unintentional and due to forgetfulness rather than an intentional decision to stop taking their medication.
Conclusion
"Mental health nurses play a central role in helping patients manage their medication more effectively" (Gray et al 2002: 283) . The introduction and increase in nurse prescribing ensures that mental health nurses have a greater than ever role to play in this important intervention. Understanding the factors that affect a person's decision to take their medication and working collaboratively with them in addressing these factors is crucial if clients are to benefit from the positive effects of medication while minimising adverse effects. In particular, mental health nurses through the use of techniques of medication management can play a positive role in preventing relapse for the individual client and thereby reducing the level of psychological and social disability resulting from this experience.
